Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Opella Healthcare UK Limited, trading as Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, United Kingdom
Maalox Plus.
Pharmaceutical Form |
---|
Oral suspension. White suspension, homogenous after shaking, with the odour and taste of lemon. |
The active components of Maalox Plus are:
Dried Aluminium Hydroxide Gel: 230mg/5ml
Magnesium Hydroxide: 200mg/5ml
Simeticone: 25mg/5ml
Also contains 224mg of sorbitol (E420), per 5ml.
For a full list of excipients, see section 6.1
Active Ingredient | Description | |
---|---|---|
Aluminium hydroxide |
Aluminium hydroxide is a slow-acting antacid. It is used to provide symptomatic relief in gastric hyperacidity. In addition, the antipeptic and demulcent activity of aluminium hydroxide helps to protect inflamed gastric mucosa against further irritation by gastric secretions. |
|
Magnesium hydroxide |
Magnesium hydroxide is practically insoluble in water and solution is not effected until the hydroxide reacts with hydrochloric acid in the stomach to form magnesium chloride. Its neutralising action is almost equal to that of sodium bicarbonate. When the dose is in excess of that required to neutralise the acid the intragastric pH may reach pH 8 or 9. Acid rebound following magnesium hydroxide is clinically insignificant. Magnesium hydroxide has an indirect cathartic effect resulting from water retention in the intestinal lumen. |
|
Simethicone |
Simethicone is a chemically inert, non-systemic gastric defoaming agent that works by altering the elasticity of interfaces of mucus-embedded bubbles in the gastrointestinal tract. The gas bubbles are thus broken down or coalesced and in this form gas is more easily eliminated through eructation or passing flatus. |
List of Excipients |
---|
Domiphen bromide |
White polyethylene terephthalate (PET) bottles with polypropylene (PP) closure and polyethylene (PE/LDPE) liner: 250ml and 355ml.
Not all pack sizes may be marketed.
Opella Healthcare UK Limited, trading as Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, United Kingdom
PL 53886/0041
Date of first authorisation: 08/09/1989
Drug | Countries | |
---|---|---|
MAALOX PLUS | Cyprus, Hong Kong, Ireland, Israel, Malta, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.